doi:10.3969/j.issn.1674-490X.2019.04.005

Abstract

Abstract: Although the therapeutic effect of adult Ph chromosome negative acute lymphocyte(Ph-ALL)is lagging behind that of childhood acute lymphoblastic leukemia, the gap is gradually narrowing with the progress of understanding the biological characteristics of ALL, which is transforming the progress of therapeutic effect. In adolescents and young adults with acute lymphoblastic leukemia adapted from pediatric protocols,risk stratification based on genetic characteristics and minimal residual disease, and adjustment of post-remission treatment further improve the therapeutic effect of patients. In recent years, immunotherapy based on monoclonal antibodies has achieved initial success in the treatment of adult Ph-ALL. In this paper, the recent developments on the treatment of Ph-ALL is briefly summarized.

Key words: acute lymphoblastic leukemia, minimal residual disease, Ph chromosome, monoclonal antibodies

CLC Number:

References

[1] PARIKH S A, LITZOW M R. Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development[J]. Future Oncol, 2014, 10(14): 2201-2212. DOI: 10.2217/fon.14.81.
[2] FREY N V, LUGER S M. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia[J]. Blood, 2015, 126(5):589-596. DOI: 10.1182/blood-2014-09-551937.
[3] ALDOSS I, STEIN A S. Advances in adult acute lymphoblastic leukemia therapy[J]. Leuk Lymphoma, 2018, 59(5):1033-1050. DOI: 10.1080/10428194.2017.1354372.
[4] HUGUET F, CHEVRET S, LEGUAY T, et al. Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial[J]. J Clin Oncol, 2018, 36(24): 2514-2523. DOI: 10.1200/JCO.2017.76.8192.
[5] ISSA G C, KANTARJIAN H M, YIN C C, et al. Prognostic impact of pretreatment cytogenetics in adult philadelphia chromosome-negative acute lymphoblastic eukemia in the era of minimal residual disease[J]. Cancer,2017, 123(3): 459-467. DOI: 10.1002/cncr.30376.
[6] ISSHIKI Y, OHWADA C, SAKAIDA E, et al. CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatricinspired chemotherapy[J]. Jpn J Clin Oncol, 2017, 47(11): 1047-1054. DOI: 10.1093/jjco/hyx126.
[7] SHORT NJ, KANTARJIAN H M, SASAKI K, et al. Prognostic significance of day 14 bone marrow evaluation in adults with philadelphia chromosome-negative acute lymphoblastic leukemia[J]. Cancer, 2016, 122(24): 3812-3820. DOI: 10.1002/cncr.30262.
[8] KUMAR A J, GIMOTTY P A, GELFAND J M, et al. Delays in post-remission chemotherapy for philadelphia chromosome negative acute lymphoblastic leukemia are associated with Inferior outcomes in patients who undergo allogeneic transplant: an analysis from ECOG 2993/MRC UK ALLXII[J]. Am J Hematol, 2016, 91(11): 1107-1112. DOI: 10.1002/ajh.24497.
[9] MAURY S, CHEVRETT S, THOMAS X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia[J]. N Engl J Med, 2016, 375(11): 1044-1053. DOI: 10.1056/NEJMoa1605085.
[10] TVITO A, ROWE J M. Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia[J]. Expert Opin Biol Ther, 2017, 17(12): 1557-1564. DOI: 0.1080/14712598.2017.1387244.
[11] JABBOUR E, RAVANDI F, KEBRIAEI P, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory philadelphia chromosome-negative acute lymphoblastic leukemialA Phase 2 clinical trial[J]. JAMA Oncol, 2018, 4(2): 230-234. DOI: 10.1001/jamaoncol.2017.2380.
[12] WOLACH O, STONE R M. Blinatumomab for the treatment of philadelphia chromosome-negative, precursor B-cell acute lymphoblastic leukemia[J]. Clin Cancer Res,2015, 21(19): 4262-4269. DOI: 10.1158/1078-0432.CCR-15-0125.
[13] SCHILLER G J, DAMON L E, COUTRE S E, et al. High-dose vincristine sulfate liposome injection, for advanced, relapsed, or refractory philadelphia chromosome-negative acute lymphoblastic aeukemia in an adolescent and young adult subgroup of a phase 2 clinical trial[J]. J Adolesc Young Adult Oncol, 2018, 7(5): 546-552. DOI: 10.1089/jayao.2018.0041.
[14] JABBOUR E, PUI C H, KANTARJIAN H. Progress and innovations in the management of adult acute lymphoblastic leukemia[J]. JAMA Oncol, 2018, 4(10):1413-1420. DOI: 10.1001/jamaoncol.
[15] SAKURA T, HAYAKAWA F, SUGIURA I, et al. High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG[J]. Leukemia, 2018, 32(3): 626-632. DOI: 10.1038/leu.2017.283.
[16] TASIAN S K, Loh M L, Hunger S P. Philadelphia chromosome-like acute lymphoblastic leukemia[J].Blood, 2017, 130(19): 2064-2072. DOI: 10.1182/blood-2017-06-743252.
[17] ARBER D A, ORAZI A, HASSERJIAN R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 27(20): 2391-2405. DOI: 10.1182/blood-2016-03-643544.
[18] TERWILLIGER T, ABDUL-HAY M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update[J]. Blood Cancer J, 2017, 7(6): e577. DOI: 10.1038/bcj.2017.53.
[19] JAIME-PEREZ J C, COLUNGA-PEDRAZA P R, GUTIERREZ-AGUIRRE C H, et al. Efficacy of mitoxantrone as frontline anthracycline during induction therapy in adults with newly diagnosed acute lymphoblastic leukemia. A single-center experience[J]. Leuk Lymphoma, 2015, 56(9): 2524-2528. DOI: 10.3109/10428194.2015.1009058.
[20] KOPRIVNIKAR J, MCCLOKEY J, FADERL S. Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia[J].Onco Targets Ther, 2017, 10: 1413-1422. DOI: 10.2147/OTT.S106810.
[21] 季静,韩颖,化罗明,等. 大剂量甲氨蝶呤化疗副作用观察及处置[J]. 医学研究与教育, 2012, 29(6): 32-34. DOI: 1674-490X(2012)06-0032-03.
[22] SEFTEL M D, NEUBERG D, ZHANG M J, et al.Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission[J]. Am J Hematol,2016, 91(3): 322-329. DOI: 10.1002/ajh.24285.
[23] TOPP M S, GÖKBUGET N, STEIN A S, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study[J]. Lancet Oncol, 2015, 16(1): 57-66. DOI: 10.1016/S1470-2045(14)71170-2.
[24] FLOWERS C R, RAMSEY S D.What can cost-effectiveness analysis tell us about chimeric antigen receptor T-Cell therapy for relapsed acute lymphoblastic leukemia? [J]. J Clin Oncol, 2018, 36(32): 3183-3185. DOI: 10.1200/JCO.2018.79.3570.
[25] MAUDE S L, LAETSCH T W, BUECHNER J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5): 439-448. DOI: 10.1200/JCO.2018.79.3570.
[26] FREY N V. CAR T cells for acute lymphoblastic leukemia[J]. Am J Hematol,2019, 94(S1): S24-S27. DOI: 10.1002/ajh.25442.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(3): 14-21.
[2]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(1): 1-9.
[3]	QI Lin,CHENG Zhiyong,ZHANG Lijun,WANG Meng,WANG Baoyan. The effect of interferon-α2b on PD-1/PD-L1 signaling pathway of HEL cells [J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(3): 1-8.
[4]	WEI Yali,SUN Chengcheng,WANG Xiaochun. Advances on vasculogenic mimicry in breast cancer [J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(2): 16-23.
[5]	. [J]. Journal of Hebei Medical College for Continuing Education, 2021, 38(1): 64-69.
[6]	. [J]. Journal of Hebei Medical College for Continuing Education, 2020, 37(6): 23-28.
[7]	. [J]. Journal of Hebei Medical College for Continuing Education, 2020, 37(4): 13-19.
[8]	. [J]. Journal of Hebei Medical College for Continuing Education, 2020, 37(3): 18-27.
[9]	. [J]. Medical Reserch and Education, 2020, 37(1): 36-40.
[10]	. [J]. Medical Reserch and Education, 2019, 36(6): 54-62.
[11]	. [J]. Medical Reserch and Education, 2019, 36(4): 59-65.
[12]	. [J]. Medical Reserch and Education, 2019, 36(2): 13-16.
[13]	. [J]. Medical Reserch and Education, 2019, 36(2): 17-22.
[14]	. [J]. Medical Reserch and Education, 2018, 35(5): 12-18.
[15]	. [J]. Medical Reserch and Education, 2018, 35(3): 55-58.